View all news

Avalanche Biotechnologies, Inc. Announced That it Has Been Awarded Two Grants from the National Eye Institute to Fund Pre-clinical Studies Related to its Novel AAV Variant Technology


October 1, 2012

Avalanche Biotechnologies, Inc. announced that it has been awarded two grants from the National Eye Institute to fund pre-clinical studies related to its novel AAV variant technology. The first grant, funded through the SBIR program with Dr. Thomas W. Chalberg as Principal Investigator, is geared toward pre-clinical development of anti-VEGF vectors for diabetic macular edema. The second grant investigates Avalanche’s delivery technology in animal models of glaucoma; this grant was funded through the STTR program and is being coordinated by Avalanche in collaboration with Cornell Weill Medical College, with Dr. Anna-Maria Demetriades as Principal Investigator. The two grants, totaling approximately $600,000, will help advance Avalanche’s technology platform for development and manufacture of AAV variants for long-term protein delivery to the eye. Avalanche’s AAV variants, which can successfully transduce retinal cells following intravitreal injection, represent a promising platform technology with multiple product opportunities for large-market and orphan disorders in ophthalmology.

Multimedia Files:

View all news